StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Seattle Genetics (SGEN), Takeda Pharmaceutical Report Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS (Brentuximab Vedotin)
October 1, 2018 6:48 AM
Seattle Genetics, Inc. (NASDAQ: SGEN) and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Management Comments
Next Articles
Seattle Genetics (SGEN) PT Raised to $105 at Leerink Partners
October 1, 2018 11:21 AM
Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma
October 1, 2018 6:45 AM
